MIO Consult
The accounting consequences of a deal are set at the term sheet, not at year end.
MIO Consult advises pharmaceutical, biotech and MedTech companies on the accounting of licensing, collaboration, M&A and partnering structures, before commitments are made and long after they are signed. Both sides of the ledger: revenue and milestone recognition under IFRS 15 and ASC 606, and the intangibles, capitalisation and expense treatment that shapes the P&L for years.
Surface the accounting consequences while commercial terms can still be changed.
Document the judgement path so finance, auditors and deal teams work from the same position.
Defend, remediate or rebuild technical positions when signed structures are challenged.
Deal teams sign. Finance teams inherit.
Licensing structures with regulatory and commercial milestones. Collaborations with cost-sharing and co-promotion rights. In-licensed assets whose capitalisation turns on judgement. These structures are negotiated in weeks and accounted for over decades, and the treatment questions surface at the worst moments: at audit, ahead of a raise, or in front of an acquirer. An independent technical read before signature is the cheapest insurance in the deal.
Four ways MIO Consult helps
Transaction Advisory
Pre-signature impact assessments, technical memos and position papers of Big-4 rigour, audit-ready documentation, and support through close, covering the deal and the processes and reporting it leaves behind. Learn more
In-House Training
Deal-accounting capability built inside your finance team, shaped around your own deal book. Corporate groups sending three or more participants can book by invoice. View courses
Frameworks
Structured, self-serve tools for transaction accounting readiness, from first assessment to full deal-room preparation. Framework sessions are available by enquiry while the full toolkit is built. Register interest
The Book
Accounting for Innovation: Revenue Recognition in the Age of Biotech Breakthroughs (2026), the practice’s thinking in permanent form. Explore the book ↗
Built on the standard itself.
MIO Consult is led by Michelle Olufeso-Nwokobia, co-developer of IFRS 15 through the joint IASB/FASB project that also produced ASC 606, engaging both boards on Roche’s behalf. Twelve years at Roche, including Global Alliances Accounting Expert and Head of Accounting External Relations, preceded by finance roles across oil and gas, telecoms and banking. The rules your deals are measured against are rules she helped write. Full profile
Professionals from organisations including
Workshop participants have joined programmes delivered via CELforPharma from these organisations. Organisation names are shown for participant-profile context and do not imply endorsement.
A transaction on your desk?
Book a 15-minute introductory call and find out in one conversation whether the structure needs a deeper look.